Tirzepatide 30mg

Description

Tirzepatide Research Peptide — 30mg

Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide widely studied for its role in metabolic pathway research. Originally developed by Eli Lilly, it represents a new class of dual-incretin receptor agonists.

Research Profile

• Targets: GLP-1R, GIPR (dual agonist)
• Molecular Weight: ~4,813 Da
• Purity: ≥98% by HPLC
• Form: Lyophilized powder
• Storage: -20°C, protect from light

Published Research

Tirzepatide has been extensively studied in the SURPASS and SURMOUNT clinical trial programs. Published data in The Lancet and NEJM describe its dual-receptor mechanism and downstream metabolic effects in research subjects.

Handling

Reconstitute with bacteriostatic water. Store reconstituted solution at 2-8°C. For in-vitro research and laboratory use only.